Occurrence of Graves' disease during retreatment with interferon-alpha 2a for chronic hepatitis C.
The present report describes a patient who developed Graves' disease 3 months after inception of retreatment with higher doses of interferon-alpha 2a for chronic hepatitis C, although the initial 6-month treatment caused no serious adverse reactions. Severe hyperthyroidism continued despite discontinuation of interferon-alpha 2a, and the patient was subsequently treated with 131I. This case suggests careful evaluation of the safety of retreatment to prevent manifestation of such a complication in the retreatment of chronic hepatitis C with interferon.
Wada
M
M
Fourth Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya.
Hiraizumi
W
W
Fujimoto
M
M
Kinugasa
A
A
Shintani
S
S
Sawada
K
K
Shimoyama
T
T
Suehiro
M
M
Fukuchi
M
M
D000328:Adult; D002908:Chronic Disease; D005260:Female; D006111:Graves Disease / Q000209:etiology* / Q000378:metabolism; D006526:Hepatitis C / Q000150:complications / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D011994:Recombinant Proteins; D012008:Recurrence
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins